



Thomas GOTTWALD, MD, PhD, Professor of Surgery, is today Member of the Executive Board and Partner of OVESCO Endoscopy AG. Prior to this, his professional industrial track record was with FRESENIUS as Global Medical Director of FRESENIUS KABI AG / Managing Director of FESENIUS KABI GmbH, and as founding president and CEO of FRESENIUS Biotech GmbH, reporting then to the CEO of Fresenius SE. In latter position he was responsible for structure and strategy from Company's foundation until filing the first international dossier with EMEA for receiving marketing approval for monoclonal antibodies against cancer.

He began his industrial career with FRESENIUS as medical director and president of FRESENIUS HemoCare GmbH, with main focus on portfolio management, basic science, clinical R&D, and business development.

Professor GOTTWALD received his medical education at the Universities of Munich and Florence, and Yale University >School of Medicine. He performed his postdoctoral research work at McMaster University in Ontario. During medical school, he was supported by two grants (Studienstiftung des Deutschen Volkes and Bayerische Begabtenförderung). His postdoctoral work was supported by both the *fortune*-program of the University of Tübingen and the German Research Council (DFG).

Professor GOTTWALD was trained at St. Gallen Business School and INSEAD.

Parallel to his today's worldwide function with OVESCO, he continues his academic work as member of the medical faculty of the University of Tübingen. He is consulting the German Ministry of Science and Education (BMBF) and various startup companies and venture capital firms. He founded and chairs T&T-Strategies and the PEXX-group (Physician Executives e.V.), bringing together individuals and organizations with vast expertise in the segments life sciences, finance, and management to share / discuss issues in these fields.